Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance
Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance
批准号:
10699934
负责人:
David Seftel
金额:
$99.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
未结题
起止时间:
2016-08-01 至 2026-05-31
关键词:
AffectAgglutinationAmericanAutoantibodiesAutoimmune DiseasesAwardBilirubinBiological AssayBiological MarkersBiological SciencesBlindedBloodBlood capillariesChronicClinicalClinical ResearchCollaborationsCollectionDataDependenceDevicesDiabetes MellitusDiabetes autoantibodiesDiabetic KetoacidosisDiagnosisDrynessEligibility DeterminationEnrollmentHemoglobinHomeHybridomasIA-2 antibodyIndividualInsulinInsulin-Dependent Diabetes MellitusInterventionIslet CellLaboratoriesLegal patentLifeLipidsLongevityMethodsNational Institute of Diabetes and Digestive and Kidney DiseasesOrganPancreasPathway interactionsPerformancePersonsPhasePlasmaProcessProductionProtocols documentationPublishing Peer ReviewsReagentRegulationReportingReproducibilityRiskRisk FactorsSamplingSerumSignal TransductionSiteSmall Business Innovation Research GrantSpecific qualifier valueSpeedSpottingsSymptomsSystemTechnologyTestingValidationWhole Bloodantibody detectiondesigndetection assaydetection limitdiabetes riskhazardinnovationinsulin dependent diabetes mellitus onsetislet cell antibodymanufacturemanufacturing qualitymanufacturing testpreventsample collectionscreening programsuccessusabilityvalidation studies
中文摘要
项目摘要
1型糖尿病是一种影响数百万美国人的慢性自身免疫性疾病,其特点是
胰腺中产生胰岛素的胰岛细胞的逐渐破坏,导致终生
对胰岛素治疗的依赖。许多1型糖尿病患者被诊断出有生命危险
糖尿病酮症酸中毒并发展出一系列危险的并发症,影响其周围的每个器官
寿命缩短。准确检测血液中是否存在抗胰岛自身抗体生物标志物
预测个人是否有患1型糖尿病的风险。自身抗体筛查计划
已被证明支持降低糖尿病酮症酸中毒发生率的干预措施,它们有助于
确定可能延缓或预防1型糖尿病发病的新干预措施的合格候选者。
然而,目前还不存在结合了准确性、速度、可扩展性和以下能力的测试方法
在家里采集样本。
正在应用的是启用生物科学第二阶段NIDDK SBIR奖R44DK111005的后续产品
2B阶段申请我们正在寻求NIDDK对FDA审批过程的支持,并
我们独特的T1D自身抗体干血斑点试验的全面质量体系实施
基于我们的创新专利抗体检测凝集-聚合酶链式反应(ADAP)技术。ADAP
是高度敏感和超特定的,并已多次被验证为最高性能的T1D
盲法同行评议已发表的临床研究中的自身抗体测定。
在具体目标1中,我们将建立全面的质量体系,以实现可靠和高质量
用于FDA研究的测试部件的制造。试剂、材料、方案和
文件控制系统将按照FDA的要求进行开发和记录。
在具体目标2中,我们将对该分析进行标准的实验室分析验证,确定
重现性、空白限度、检测限度和定量限度以及执行
在测试样品中添加常见掺杂物进行干扰分析。
在具体目标3中,我们将与全国合作进行临床验证,如果需要,
全球临床标本采集点,建立与谓词装置的非劣势。
。为了这个
英文摘要
Project Summary
Type 1 diabetes, a chronic autoimmune disorder that affects millions of Americans is characterized by
the progressive destruction of the insulin-producing islet cells of the pancreas, resulting in life-long
dependency on insulin therapy. Many people with type 1 diabetes are diagnosed with life-threatening
diabetic ketoacidosis and develop a panoply of perilous complications affecting every organ over their
shortened life spans. Testing for the presence of anti-islet autoantibody biomarkers in blood accurately
predicts whether individuals are at risk for developing type 1 diabetes. Autoantibody screening programs
have been shown to support interventions that reduce the rates of diabetic ketoacidosis and they help
identify eligible candidates for new interventions that may delay or prevent the onset of type 1 diabetes.
However, no current testing method exists that combines accuracy, speed, scalability, and the ability to
collect samples at home.
In application is a follow-on to Enable Biosciences Phase 2 NIDDK SBIR Award R44DK111005
Phase 2B application we are seeking NIDDK support for the process of FDA clearance and
comprehensive quality system implementation of our unique dried blood spot test for T1D autoantibodies
based on our innovative patented Antibody Detection by Agglutination-PCR (ADAP) technology. ADAP
is highly sensitive and ultra-specific and has been repeatedly validated as a top-performing T1D
autoantibody assay in blinded peer-reviewed published clinical studies.
In Specific Aim 1, we will develop a comprehensive quality system to allow for reliable and high-quality
manufacturing of test components to be used for the FDA study. Reagents, materials, protocols, and
document control systems will be developed and documented in compliance with FDA requirements.
In Specific Aim 2, we will perform standard laboratory analytical validation of the assay, determining the
reproducibility, limit of blank, limit of detection and limit of quantification, as well as performing
interference analysis by spiking in common adulterants into test samples.
In Specific Aim 3, we will perform our clinical validation in collaboration with nationwide and, if needed,
global clinical specimen collection sites to establish non-inferiority with the predicate device.
. For this
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk
-
批准号:10020787
-
项目类别:
-
资助金额:$74.12万
-
财政年份:2019
-
负责人:David Seftel
-
依托单位:
Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk
-
批准号:9910015
-
项目类别:
-
资助金额:$74.66万
-
财政年份:2019
-
负责人:David Seftel
-
依托单位:
Multiplex food allergy diagnostic based on IgE immunologic markers
-
批准号:10011621
-
项目类别:
-
资助金额:$84.58万
-
财政年份:2018
-
负责人:David Seftel
-
依托单位:
An Ultrasensitive, High-Throughput, and Low-Cost Autoimmunity Panel for the Early Diagnosis and Improved Treatment of Type 1 Diabetes
-
批准号:9559575
-
项目类别:
-
资助金额:$74.98万
-
财政年份:2016
-
负责人:David Seftel
-
依托单位:
Antibody-Detection-by-Agglutination-PCR (ADAP): An Ultra-Sensitive, High-Throughput, Multiplexable Tool for T1D Diagnosis and Monitoring
-
批准号:9185244
-
项目类别:
-
资助金额:$22.44万
-
财政年份:2016
-
负责人:David Seftel
-
依托单位:
海外基金